0001415889-23-012898.txt : 20230905
0001415889-23-012898.hdr.sgml : 20230905
20230905160523
ACCESSION NUMBER: 0001415889-23-012898
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230816
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harmon Cyrus
CENTRAL INDEX KEY: 0001831410
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39712
FILM NUMBER: 231235726
MAIL ADDRESS:
STREET 1: C/O OLEMA PHARMACEUTICALS, INC.
STREET 2: 512 2ND STREET, 4TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94107
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001750284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 300409740
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 BRANNAN STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
BUSINESS PHONE: (415) 651-3316
MAIL ADDRESS:
STREET 1: 780 BRANNAN STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
4/A
1
form4a-09052023_040904.xml
X0508
4/A
2023-08-16
2023-08-17
0001750284
Olema Pharmaceuticals, Inc.
OLMA
0001831410
Harmon Cyrus
C/O OLEMA PHARMACEUTICALS, INC.
780 BRANNAN ST
SAN FRANCISCO
CA
94103
true
false
false
false
1
Common Stock
2023-08-16
4
S
0
15000
10.14
D
1023714
D
The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.
On August 17, 2023, the reporting person filed a Form 4 that inadvertently excluded the weighted average sale price for the transaction. This amendment is being filed solely to report that the weighted average sale price for the transaction reported was $10.14, and the range of prices were between $9.765 and $10.65. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Shane Kovacs, Attorney-in-Fact
2023-09-05